Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБУЗ «Областная психиатрическая больница им. К.Р. Евграфова», Пенза, Россия
Список исп. литературыСкрыть список 1. WHO Collaborating Centre for Drug Statistics Methodology [Electronic resource] (Access date: 15.07.2019). URL: http://www.whocc.no 2. Weissman MM. Treatment of Depression: Bridging the 21st Century. American Psychiatric Press. Washington, DC, 2001. 3. Lacasse JR, Leo J. Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature. PLoS Med 2005; 2 (12). 4. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 2008; 69: 4–7. 5. Macher J-P, Crocq M-A. Treatment goals: response and nonresponse. Dialogues Clin Neurosci 2004; 6 (1): 83–91. 6. Duman EN, Kesim M, Kadioglu M et al. Possible Involvement of Opioidergic and Serotonergic Mechanisms in Antinociceptive Effect of Paroxetine in Acute Pain. J Pharmaceutical Sci 2004; 94 (2): 161–5. 7. Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine. J Mol Neurosci 2002; 18 (1–2): 143–9. 8. Schwarz MJ, Ackenheil M. The role of substance P in depression. Dialogues Clin Neurosci 2002; 4 (1): 21–9. 9. Weber MM, Emrich HM. Current and Historical Concepts of Opiate Treatment in Psychiatric Disorders. Int Clin Psychopharmacol 1988; 3 (3): 255–66. 10. Heal DJ, Smith SL, Gosden J et al. Amphetamine, past and present – a pharmacological and clinical perspective. J Clin Psychopharmacol 2013; 27 (6): 479–96. 11. Walker BC, Walker SR. Trends and Changes in Drug Research and Development. Lancaster: Kluwer Academic Publishers, 1988. 12. Watanabe T, Wada H. Histaminergic Neurons. Boca Raton, US, CRC Press, 1991. 13. Jennings L. Antidepressants. In: Grossberg G, Kinsella L (eds). Clinical Psychopharmacology for Neurologists. Cham, Springer, 2018; p. 45–71. 14. Кукес В.Г. Клиническая фармакология. Изд. 3-е. М.: ГЭОТАР-Медиа, 2006. / Kukes V.G. Klinicheskaia farmakologiia. Izd. 3-e. M.: GEOTAR-Media, 2006. [in Russian]. 15. Терапия антидепрессантами и другие методы лечения депрессивных расстройств: Доклад Рабочей группы CINP на основе обзора доказательных данных. Под ред. Т. Багай, Х. Грунце, Н. Сарториус. Перевод на русский язык подготовлен в Московском НИИ психиатрии Росздрава. Под ред. В.Н. Краснова. М., 2008. / Terapiia antidepressantami i drugie metody lecheniia depressivnykh rasstroistv: Doklad Rabochei gruppy CINP na osnove obzora dokazatel'nykh dannykh. Pod red. T. Bagai, Kh. Gruntse, N. Sartorius. Perevod na russkii iazyk podgotovlen v Moskovskom NII psikhiatrii Roszdrava. Pod red. V.N. Krasnova. M., 2008. [in Russian]. 16. Sharma T, Guski LS, Freund N et al. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ 2016; 352: i65. 17. Lenzer J. Antidepressants double suicidality in children, says FDA. BMJ 2006; 332: 626. 18. Stone M, Laughren T, Jones ML et al. Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009; 339: b2880. 19. Olfson M, Marcus SC, Shaffer D. Antidepressant Drug Therapy and Suicide in Severely Depressed Children and Adults: A case-control study. Arch Gen Psychiatry 2006; 63 (8). 20. Valuck RJ, Orton HD, Libby AM. Antidepressant Discontinuation and Risk of Suicide Attempt. J Clin Psychiatry 2009; 70 (8): 1069–77. 21. Jick H, Kaye JA, Jick SS. Antidepressants and the Risk of Suicidal Behaviors. JAMA 2004; 292 (3): 338–43. 22. Nauman A. Adverse Effects of Anti-depressants. Ornate Health 2013 [Electronic resource] (Access date: 15.07.2019). URL: http://ornatehealth.com/adverse-effects-of-anti-depressants/ 23. Bridge JA, Iyengar S, Salary CB et al. Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment: A Meta-analysis of Randomized Controlled Trials. JAMA 2007; 297 (15): 1683–96. 24. Beasley CM Jr, Ball SG, Nilsson ME et al. Fluoxetine and Adult Suicidality Revisited. J Clin Psychopharmacol 2007; 27 (6): 682–6. 25. Gibbons RD, Brown CH, Hur K et al. Suicidal Thoughts and Behavior with Antidepressant Treatment: Reanalysis of the Randomized Placebo-Controlled Studies of Fluoxetine and Venlafaxine. Arch Gen Psychiatry 2012; 69 (6): 580–7. 26. Warner CH, Bobo W, Warner C et al. Antidepressant discontinuation syndrome. Am Fam Physician 2006; 74 (3): 449–56. 27. Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol 2015; 5 (6): 357–68. 28. Fornaro M, Anastasia A, Novello S et al. The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: An integrative review of evidence, mechanisms, and clinical implications. Pharmacological Research 2019;139: 494–502. 29. Pringle A, McCabe C, Cowen PJ et al. Antidepressant treatment and emotional processing: can we dissociate the roles of serotonin and noradrenaline? J Psychopharmacol 2013; 27 (8): 719–31. 30. Sansone RA, Sansone LA. SSRI-Induced Indifference. Psychiatry (Edgmont) 2010; 7 (10): 14–8. 31. Bond DJ, Noronha MM, Kauer-Sant'Anna M et al. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry 2008; 69 (10): 1589–1601. 32. Александров А.А. Биполярное аффективное расстройство: диагностика, клиника, течение, бремя болезни. Медицинские новости. 2007; 12. / Aleksandrov A.A. Bipoliarnoe affektivnoe rasstroistvo: diagnostika, klinika, techenie, bremia bolezni. Meditsinskie novosti. 2007; 12. [in Russian] 33. Amit BH, Weizman A. Antidepressant Treatment for Acute Bipolar Depression: An Update. Depress Res Treat 2012; 2012; 684725. 34. Montejo AL, Montejo L, Baldwin DS. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry 2018; 17 (1): 3–11. 35. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29 (3): 259–66. 36. Ozmenler NK, Karlidere T, Bozkurt A et al. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol 2008; 23 (4): 321–6. 37. Melton ST. How Is Antidepressant-Associated Sexual Dysfunction Managed? Medscape Pharmacists. August 31, 2012 [Electronic resource]. (Access date: 15.07.2019). URL: http://www.medscape.com/ viewarticle/769813 38. Федорова О.А. Биполярное аффективное расстройство: диагностика, клиника, течение, бремя болезни. Украинский медицинский журнал. 2013. [Электронный ресурс] (Дата обращения: 15.07.2019). URL: http://www.umj.com.ua/article/67974/ sindrom-inicialnoj-trevogi-prakticheskie-rekomendacii / Fedorova O.A. Bipoliarnoe affektivnoe rasstroistvo: diagnostika, klinika, techenie, bremia bolezni. Ukrainskii meditsinskii zhurnal. 2013. [Elektronnyi resurs] (Data obrashcheniia: 15.07.2019). URL: http://www.umj.com.ua/article/67974/sindrom-inicialnoj-trevogi-prakticheskie-rekomendacii [in Russian] 39. Регистр лекарственных средств России [Электронный ресурс] (Дата обращения: 15.07.2019). URL: http://www.rlsnet.ru / Registr lekarstvennykh sredstv Rossii [Elektronnyi resurs]. (Data obrashcheniia: 15.07.2019). URL: http://www.rlsnet.ru [in Russian] 40. Государственный реестр лекарственных средств [Электронный ресурс] (Дата обращения: 15.07.2019). URL: http://grls.rosminzdrav.ru / Gosudarstvennyi reestr lekarstvennykh sredstv [Elektronnyi resurs] (Data obrashcheniia: 15.07.2019). URL: http://grls.rosminzdrav.ru [in Russian] 41. Рациональный выбор лекарств на основе индекса информационного спроса [Электронный ресурс]. Газета РЛС. 2008; 3 (Дата обращения: 15.07.2019). URL: http://www.rlsnet.ru/news_ 295.htm / Ratsional'nyi vybor lekarstv na osnove indeksa informatsionnogo sprosa [Elektronnyi resurs]. Gazeta RLS. 2008; 3 (Data obrashcheniia: 15.07.2019). URL: http://www.rlsnet.ru/news_295.htm [in Russian] 42. Вышковский Г.Л. Методология оптимального выбора фаз маркетингового воздействия при медиапланировании. Реклама. Теория и практика. 2007; 2 (20). / Vyshkovskii G.L. Metodologiia optimal'nogo vybora faz marketingovogo vozdeistviia pri mediaplanirovanii. Reklama. Teoriia i praktika. 2007; 2 (20). [in Russian] 43. Free US. Outpatient Drug Usage Statistics [Electronic resource] ClinCalc DrugStats Database (Access date: 15.07.2019). URL: http://clincalc.com/ DrugStats/ 44. Мосолов С.Н. Клиническое применение современных антидепрессантов. СПб., Медицинское информационное агентство, 1995. / Mosolov S.N. Klinicheskoe primenenie sovremennykh antidepressantov. SPb., Meditsinskoe informatsionnoe agentstvo, 1995. [in Russian] 45. Мосолов С.Н. Клиническое применение современных антидепрессантов. РМЖ. 2005; 13 (12): 852–57. / Mosolov S.N. Klinicheskoe primenenie sovremennykh antidepressantov. RMZh. 2005; 13 (12): 852–57. [in Russian] 46. Смулевич А.Б. Антидепрессанты в общемедицинской практике. Consilium Medicum. 2002; 4 (5). / Smulevich A.B. Antidepressants in General medical practice. Consilium Medicum. 2002; 4 (5). [in Russian] 47. Дробижев М.Ю., Овчинников А.А. Зачем нужна современная классификация антипсихотиков? Русский медицинский журнал. 2012; 20 (29): 1449–57. / Drobizhev M.Iu., Ovchinnikov A.A. Zachem nuzhna sovremennaia klassifikatsiia antipsikhotikov? Russkii meditsinskii zhurnal. 2012; 20 (29): 1449–57. [in Russian] 48. Ashton H. Drug newsletter. Northern Regional Health Authority. Newcastle upon Tyne: Wolfson Unit of Clinical Pharmacology Royal Victoria Infirmary [Electronic resource] 1985 (Access date: 15.07.2019). URL: http://benzo.org.uk/drcha.htm 49. Федеральное руководство по использованию лекарственных средств (формулярная система). Под ред. А.Г.Чучалина, Ю.Б.Белоусова, С.П.Голицина и др. Выпуск XIV. М.: Человек и лекарство, 2013. / Federal'noe rukovodstvo po ispol'zovaniiu lekarstvennykh sredstv (formuliarnaia sistema). Pod red. A.G.Chuchalina, Iu.B.Belousova, S.P.Golitsina i dr. Vypusk XIV. M.: Chelovek i lekarstvo, 2013. [in Russian] 50. Benzodiazepine Equivalency Table [Electronic resource]. Revised April 2007 (Access date: 15.07.2019). URL: http://benzo.org.uk/bzequiv.htm 51. Jakubovski E, Varigonda AL, Freemantle N et al. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. Am J Psychiatry 2016; 173 (2): 174–83. 52. Hayasaka Y, Purgato M, Magni LR et al. Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. J Affect Disord 2015; 180: 179–84. 53. Ali IM. Long-term treatment with antidepressants in primary care: Are sub-therapeutic doses still being used? Psychiatric Bulletin 1998; 22 (1): 15–9. 54. WHO Model List of Essential Medicines 18th list, April 2013 (Final Amendments – October 2013) [Electronic resource] (Access date: 15.07.2019). URL: http://www.who.int/iris/bitstream/10665/93142/1/ EML_18_eng.pdf